Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas

Ítems similars

• Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma – rationale for comprehensive mutation profiling
  per: Chaft, Jamie E., et al.
  Publicat: (2011)
• Association of KRAS and EGFR Mutations with Survival in Patients with Advanced Lung Adenocarcinomas
  per: Johnson, Melissa L., et al.
  Publicat: (2012)
• Lungs don’t forget: Comparison of the KRAS and EGFR mutation profile and survival of “collegiate smokers” and never smokers with advanced lung cancers
  per: Varghese, Anna M., et al.
  Publicat: (2013)
• Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.
  per: Offin, Michael, et al.
  Publicat: (2018)
• Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation
  per: Oxnard, Geoffrey R., et al.
  Publicat: (2010)